ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.